MA30876B1 - Anticorps de la lymphotoxine-alpha - Google Patents
Anticorps de la lymphotoxine-alphaInfo
- Publication number
- MA30876B1 MA30876B1 MA31855A MA31855A MA30876B1 MA 30876 B1 MA30876 B1 MA 30876B1 MA 31855 A MA31855 A MA 31855A MA 31855 A MA31855 A MA 31855A MA 30876 B1 MA30876 B1 MA 30876B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- lymphotoxin
- alpha
- chimeric
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Theoretical Computer Science (AREA)
- Endocrinology (AREA)
- General Business, Economics & Management (AREA)
- Physics & Mathematics (AREA)
- Business, Economics & Management (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Abstract
L'INVENTION PORTE SUR DIFFÉRENTS ANTICORPS QUI SE FIXENT À LA LYMPHOTOXINE-ALPHA, SUR LES MÉTHODES D'ÉLABORATION DE TELS ANTICORPS, SUR DES COMPOSITIONS ET ARTICLES INCORPORANT DE TELS ANTICORPS, ET SUR LEURS UTILISATIONS POUR LE TRAITEMENT, PAR EXEMPLE, DE TROUBLES AUTOIMMUNES. LESDITS ANTICORPS COMPRENNENT DES ANTICORPS MURINS, CHIMÈRES ET HUMANISÉS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82925706P | 2006-10-12 | 2006-10-12 | |
| US93899907P | 2007-05-18 | 2007-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30876B1 true MA30876B1 (fr) | 2009-11-02 |
Family
ID=39430415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31855A MA30876B1 (fr) | 2006-10-12 | 2009-05-08 | Anticorps de la lymphotoxine-alpha |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7923011B2 (fr) |
| EP (1) | EP2084188A2 (fr) |
| JP (1) | JP5298021B2 (fr) |
| KR (1) | KR20090078349A (fr) |
| AR (1) | AR063257A1 (fr) |
| AU (1) | AU2007324135B2 (fr) |
| BR (1) | BRPI0715580A2 (fr) |
| CA (1) | CA2665644A1 (fr) |
| CL (1) | CL2007002926A1 (fr) |
| CO (1) | CO6220841A2 (fr) |
| CR (1) | CR10705A (fr) |
| IL (1) | IL197937A0 (fr) |
| MA (1) | MA30876B1 (fr) |
| MX (1) | MX2009003774A (fr) |
| NO (1) | NO20091841L (fr) |
| NZ (1) | NZ576032A (fr) |
| PE (1) | PE20080980A1 (fr) |
| RU (1) | RU2486201C2 (fr) |
| TW (1) | TWI414531B (fr) |
| UA (1) | UA94484C2 (fr) |
| WO (1) | WO2008063776A2 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036443A1 (fr) * | 2008-09-26 | 2010-04-01 | Eureka Therapeutics, Inc. | Lignées cellulaires et protéines avec motif de glycosylation variant |
| MX2011003352A (es) * | 2008-09-30 | 2011-05-02 | Genentech Inc | Marcadores biologicos predictivos de la respuesta de la artritis reumatoide a antagonistas de linfotoxina. |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2011060015A1 (fr) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Procédés et compositions de détection de protéines cibles |
| MX2012011629A (es) * | 2010-04-07 | 2013-03-05 | Abbvie Inc | Proteinas de union a tnf-alfa. |
| EP2578232A4 (fr) | 2010-06-02 | 2013-11-20 | Dainippon Sumitomo Pharma Co | Médicament de traitement pour des maladies auto-immunes et des maladies allergiques |
| CN102621310B (zh) * | 2011-01-28 | 2014-07-02 | 上海科新生物技术股份有限公司 | 胶体金层析法抗u1-rnp抗体检测试纸及其制备方法 |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| WO2013114164A1 (fr) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Procédé d'obtention d'une composition glycoprotéique ayant une concentration accrue d'afucosylation |
| WO2013177062A2 (fr) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Procédés pour améliorer la sécurité du transport à travers la barrière hémato-encéphalique |
| US12565524B2 (en) * | 2012-05-29 | 2026-03-03 | North Carolina Central University | Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues |
| GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| WO2015057066A1 (fr) * | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Anticorps et conjugué d'anticorps glycomanipulés et procédés pour leur préparation |
| WO2015057906A1 (fr) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Agonistes 1 du récepteur cd200 |
| KR101820572B1 (ko) * | 2015-08-12 | 2018-01-19 | 가톨릭대학교 산학협력단 | 만성골수성백혈병에 관한 정보 제공 방법 |
| CN108431026B (zh) | 2015-11-02 | 2023-02-17 | 豪夫迈·罗氏有限公司 | 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| US12054558B2 (en) | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| GB201812571D0 (en) | 2018-08-01 | 2018-09-12 | Univ College Dublin Nat Univ Ireland Dublin | A method of diagnosing or prognosing psoriatic arthritis |
| EP3880696A1 (fr) * | 2018-11-16 | 2021-09-22 | Consejo Superior de Investigaciones Cientificas | Variants d'étanercept ayant un effet thérapeutique amélioré |
| CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
| WO2025149667A1 (fr) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Conjugués anticorps-médicament et leurs utilisations |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) * | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4920196A (en) | 1982-07-30 | 1990-04-24 | Genentech, Inc. | Human lymphotoxin |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| IL75318A (en) * | 1984-05-31 | 1994-08-26 | Genentech Inc | Recombinant human memotoxin and methods for its recombinant production |
| US4959457A (en) | 1984-05-31 | 1990-09-25 | Genentech, Inc. | Anti-lymphotoxin |
| US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| CA1338518C (fr) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Heteroconjugues d'anticorps pour tuer les cellules infectees par le vih |
| JPH023698A (ja) | 1988-06-20 | 1990-01-09 | Denki Kagaku Kogyo Kk | ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6475787B1 (en) | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5670149A (en) | 1990-06-27 | 1997-09-23 | Biogen, Inc. | Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof |
| US7030080B2 (en) | 1990-06-27 | 2006-04-18 | Biogen, Inc. | Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof |
| DK0536299T3 (da) | 1990-06-27 | 2001-07-09 | Univ California | Overfladekompleksbundet lymfotolksin |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| EP0590058B1 (fr) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | ANTICORP HUMANISE specifique pour heregulin |
| EP0604580A1 (fr) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab') 2? |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| RU2048521C1 (ru) * | 1992-05-25 | 1995-11-20 | Научно-Исследовательский Конструкторско-Технологический Институт Биологически Активных Веществ | Способ получения полипептида со свойствами лимфотоксина человека |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US20050255104A1 (en) | 1993-01-29 | 2005-11-17 | Centocor, Inc. | Methods of treating psoriasis using anti-TNF receptor fusion proteins |
| US5747023A (en) | 1994-07-01 | 1998-05-05 | Genentech, Inc. | Cancer therapy using lymphotoxin |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| US5747373A (en) * | 1996-09-24 | 1998-05-05 | Taiwan Semiconductor Manufacturing Company Ltd. | Nitride-oxide sidewall spacer for salicide formation |
| US7255854B1 (en) | 1996-10-25 | 2007-08-14 | Biogen, Inc. | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases |
| BR9712670A (pt) | 1996-10-25 | 1999-10-19 | Biogen Inc | Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AU4930399A (en) * | 1998-07-29 | 2000-02-21 | Kyowa Hakko Kogyo Co. Ltd. | Novel Polypeptide |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| HUP0104865A3 (en) * | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1159003E (pt) | 1999-03-02 | 2011-02-22 | Centocor Inc | Anti-tnf alfa na terapêutica da asma resistente a esteróides |
| EP2275540B1 (fr) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Procédé de contrôle de l'activité de molécule fonctionnelle immunologique |
| CA2388245C (fr) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues |
| US7056695B2 (en) | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| US20060034828A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US20060029604A1 (en) | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| US20060034830A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| NZ525793A (en) | 2000-10-13 | 2008-04-30 | Biogen Idec Inc | Humanized anti-LT-beta-R antibodies |
| EP1345968A2 (fr) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2003040307A2 (fr) | 2001-07-27 | 2003-05-15 | Human Genome Sciences, Inc. | Elements de la famille des ligands heteromultimeres du tnf |
| EP1423510A4 (fr) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
| PL213948B1 (pl) * | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| WO2003047510A2 (fr) | 2001-11-30 | 2003-06-12 | Centocor, Inc. | Anticorps anti-tnf, compositions, procedes et utilisations |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7273707B2 (en) * | 2002-02-08 | 2007-09-25 | Wyeth | Method of identifying a modulator of a LTβR complex signaling pathway |
| EP1498490A4 (fr) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | Procede de production de composition anticorps |
| WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
| WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
| CA2481920A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition anticorps |
| EP1498491A4 (fr) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| WO2003089575A2 (fr) | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Anticorps se liant specifiquement au tl5 |
| CN1678625A (zh) | 2002-07-01 | 2005-10-05 | 比奥根艾迪克Ma公司 | 人源化抗淋巴毒素β受体的抗体 |
| US6873910B2 (en) * | 2002-10-22 | 2005-03-29 | Qualcomm Incorporated | Procedure for searching for position determination signals using a plurality of search modes |
| US20060147448A1 (en) | 2002-10-31 | 2006-07-06 | Jennifer Gommerman | Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| RS20050481A (sr) | 2002-12-20 | 2007-08-03 | Biogen Idec Ma Inc., | Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima |
| EP2330213A1 (fr) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (fr) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| KR100772800B1 (ko) | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| US20050266004A1 (en) * | 2003-12-08 | 2005-12-01 | Jill Giles-Komar | Anti-human lymphotoxin alpha antibodies, compositions, methods and uses |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| JP2008515772A (ja) | 2004-07-21 | 2008-05-15 | グライコフィ, インコーポレイテッド | Gal2GlcNAc2Man3GlcNAc2グリコフォームを支配的に含む免疫グロブリン |
| CA2573554A1 (fr) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulines comprenant principalement une glycoforme man<sb>5</sb>glcnac<sb>2</sb> |
| EP1771479A1 (fr) | 2004-07-21 | 2007-04-11 | Glycofi, Inc. | Immunoglobulines comprenant principalement une glycoforme glcnacma5glcnac2 |
| CA2573541A1 (fr) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb> |
| CA2577133A1 (fr) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Variants de polypeptides dotes d'une fonction effectrice modifiee |
| JP2006228261A (ja) | 2005-02-15 | 2006-08-31 | Micron Technology Inc | デジット線絶縁ゲートの負電圧駆動 |
| EP1888649A2 (fr) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc |
-
2007
- 2007-10-11 NZ NZ576032A patent/NZ576032A/en not_active IP Right Cessation
- 2007-10-11 AU AU2007324135A patent/AU2007324135B2/en not_active Ceased
- 2007-10-11 JP JP2009532587A patent/JP5298021B2/ja not_active Expired - Fee Related
- 2007-10-11 RU RU2009117680/10A patent/RU2486201C2/ru not_active IP Right Cessation
- 2007-10-11 PE PE2007001374A patent/PE20080980A1/es not_active Application Discontinuation
- 2007-10-11 CA CA002665644A patent/CA2665644A1/fr not_active Abandoned
- 2007-10-11 TW TW096138038A patent/TWI414531B/zh not_active IP Right Cessation
- 2007-10-11 MX MX2009003774A patent/MX2009003774A/es active IP Right Grant
- 2007-10-11 KR KR1020097009641A patent/KR20090078349A/ko not_active Ceased
- 2007-10-11 WO PCT/US2007/081154 patent/WO2008063776A2/fr not_active Ceased
- 2007-10-11 EP EP07871155A patent/EP2084188A2/fr not_active Withdrawn
- 2007-10-11 US US11/871,136 patent/US7923011B2/en not_active Expired - Fee Related
- 2007-10-11 BR BRPI0715580-8A2A patent/BRPI0715580A2/pt not_active IP Right Cessation
- 2007-10-11 AR ARP070104513A patent/AR063257A1/es not_active Application Discontinuation
- 2007-10-11 CL CL200702926A patent/CL2007002926A1/es unknown
- 2007-10-11 UA UAA200904634A patent/UA94484C2/uk unknown
-
2009
- 2009-04-03 CR CR10705A patent/CR10705A/es unknown
- 2009-04-05 IL IL197937A patent/IL197937A0/en unknown
- 2009-05-08 MA MA31855A patent/MA30876B1/fr unknown
- 2009-05-11 NO NO20091841A patent/NO20091841L/no not_active Application Discontinuation
- 2009-05-12 CO CO09048130A patent/CO6220841A2/es active IP Right Grant
-
2011
- 2011-02-11 US US13/026,069 patent/US8216807B2/en not_active Expired - Fee Related
- 2011-02-11 US US13/026,123 patent/US8541552B2/en not_active Expired - Fee Related
-
2012
- 2012-07-06 US US13/543,485 patent/US8642740B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200825101A (en) | 2008-06-16 |
| WO2008063776A2 (fr) | 2008-05-29 |
| WO2008063776A3 (fr) | 2009-03-05 |
| US20090285830A1 (en) | 2009-11-19 |
| US20130011412A1 (en) | 2013-01-10 |
| JP5298021B2 (ja) | 2013-09-25 |
| CR10705A (es) | 2009-05-07 |
| BRPI0715580A2 (pt) | 2014-06-10 |
| RU2009117680A (ru) | 2010-11-20 |
| AR063257A1 (es) | 2009-01-14 |
| UA94484C2 (uk) | 2011-05-10 |
| CA2665644A1 (fr) | 2008-05-29 |
| TWI414531B (zh) | 2013-11-11 |
| US8216807B2 (en) | 2012-07-10 |
| RU2486201C2 (ru) | 2013-06-27 |
| KR20090078349A (ko) | 2009-07-17 |
| PE20080980A1 (es) | 2008-09-02 |
| NZ576032A (en) | 2012-03-30 |
| US8642740B2 (en) | 2014-02-04 |
| CL2007002926A1 (es) | 2008-05-16 |
| US20110150865A1 (en) | 2011-06-23 |
| AU2007324135B2 (en) | 2013-06-27 |
| US8541552B2 (en) | 2013-09-24 |
| AU2007324135A1 (en) | 2008-05-29 |
| CO6220841A2 (es) | 2010-11-19 |
| MX2009003774A (es) | 2009-04-22 |
| IL197937A0 (en) | 2011-08-01 |
| NO20091841L (no) | 2009-07-13 |
| US20110208673A1 (en) | 2011-08-25 |
| JP2010506568A (ja) | 2010-03-04 |
| EP2084188A2 (fr) | 2009-08-05 |
| US7923011B2 (en) | 2011-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52773B1 (fr) | Anticorps anti-cd3 et leurs utilisations | |
| BR0211953A (pt) | Inibidores de rota complementar ligando-se a cs e csa sem prevenção da formação de csb | |
| MA33285B1 (fr) | Anticorps anti-cxcr4 pour le traitement du vih | |
| TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
| GEP20104922B (en) | Antibodies to m-csf | |
| SG10201407388XA (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| MA40041B1 (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA33052B1 (fr) | Variants de liaison anti-albumine sérique améliorés | |
| MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
| EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
| MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| MA32654B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| TW200709817A (en) | Platform antibody compositions | |
| MA31963B1 (fr) | Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
| MA37946B1 (fr) | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde | |
| MA54975B1 (fr) | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation | |
| MX2009003774A (es) | Anticuerpos para linfotoxina-alfa. | |
| MA33051B1 (fr) | Variants de liaison anti-albumine serique ameliores | |
| MA30331B1 (fr) | ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION | |
| MA33753B1 (fr) | Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo |